{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:13:50Z","timestamp":1785510830874,"version":"3.56.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002349","name":"Academy of Scientific Research and Technology","doi-asserted-by":"publisher","award":["FRM-SGO-CYC#8"],"award-info":[{"award-number":["FRM-SGO-CYC#8"]}],"id":[{"id":"10.13039\/501100002349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","award":["PC3448"],"award-info":[{"award-number":["PC3448"]}],"id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007787","name":"National Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118142","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:07:15Z","timestamp":1757491635000},"page":"118142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting EGFR with thiazolidin-4-ones: Structure-guided design, synthesis, and in silico profiling for anticancer drug discovery"],"prefix":"10.1016","volume":"300","author":[{"given":"Wessam I.","family":"Elsisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham F.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin M.","family":"Syam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal E.F.","family":"Abd-Ellatef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaia S.","family":"Abd El-Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118142_bib1","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.2174\/1871520622666220404082648","article-title":"Heterocyclic compounds: importance in anticancer drug discovery","volume":"22","author":"Kumar","year":"2022","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib2","author":"Qadir"},{"key":"10.1016\/j.ejmech.2025.118142_bib3","first-page":"997","article-title":"Synthesis and characterization of new thiazolidinone and oxazolidinone heterocyclic derivatives from 2-Marcapto-1,3,4-Thiadiazole compounds","volume":"6","author":"Salman","year":"2022","journal-title":"Chem. Methodol."},{"key":"10.1016\/j.ejmech.2025.118142_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2021.100105","article-title":"Synthesis of novel coumarin-thiazolidine-2,4-dione derivatives: an approach to computational studies and biological evaluation","volume":"3","author":"Mangasuli","year":"2021","journal-title":"Results Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jare.2020.01.008","article-title":"An overview on medicinal perspective of thiazolidine-2,4-dione: a remarkable scaffold in the treatment of type 2 diabetes","volume":"23","author":"Bansal","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmech.2013.11.017","article-title":"4-Thiazolidinones: the advances continue","volume":"72","author":"Tripathi","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/AAC.21.1.5","article-title":"Mode of action of the biotin antimetabolites actithiazic acid and \u03b1-methyldethiobiotin","volume":"21","author":"Eisenberg","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118142_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/molecules23030685","article-title":"Thiazoles and thiazolidinones as COX\/LOX inhibitors","volume":"23","author":"Liaras","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118142_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104827","article-title":"Design, synthesis and molecular docking of new pyrazole-thiazolidinones as potent anti-inflammatory and analgesic agents with TNF-\u03b1 inhibitory activity","volume":"111","author":"Abd El-Karim","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104985","article-title":"Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma","volume":"112","author":"Fouad","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bioorg.2018.01.023","article-title":"Discovery of thiazolin-4-one-based aromatic sulfamates as a new class of carbonic anhydrase isoforms I, II, IV, and IX inhibitors","volume":"77","author":"Nocentini","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib12","doi-asserted-by":"crossref","first-page":"43596","DOI":"10.1021\/acsomega.3c04662","article-title":"Vetting of new 2,5-Bis (2,2,2-trifluoroethoxy) phenyl-linked 1,3-Thiazolidine-4-one derivatives as AURKA and VEGFR-2 inhibitor antiglioma agents assisted with in vitro and in silico studies","volume":"8","author":"D Shankara","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118142_bib13","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-023-10106-1","article-title":"Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics","author":"Sharma","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2025.118142_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/17568919.2024.2437976","article-title":"New thiazolidin-4-ones as anti-cervical cancer agents targeting EGFR: design, synthesis, and computational studies","volume":"17","author":"Bawazir","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.bmc.2019.03.049","article-title":"Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2","volume":"27","author":"Qi","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pharmthera.2004.01.002","article-title":"Signaling through the epidermal growth factor receptor during the development of malignancy","volume":"102","author":"Grandis","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118142_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.118142_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118142_bib19","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118142_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","article-title":"Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor \u03b1","volume":"110","author":"Garrett","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118142_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118142_bib22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2025.118142_bib23","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1080\/14756366.2022.2128797","article-title":"Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors","volume":"37","author":"Zuo","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib24","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202107103","article-title":"EGFR-RAS-MAPK signaling is confined to the plasma membrane and associated endorecycling protrusions","volume":"220","author":"Surve","year":"2021","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118142_bib25","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1002\/1878-0261.13500","article-title":"Activation of the EGFR\/PI3K\/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer","volume":"17","author":"Novoplansky","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118142_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jcb.21475","article-title":"STAT-Mediated EGFR signaling in cancer","volume":"102","author":"Quesnelle","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2025.118142_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118244","article-title":"Recent achievements in molecular insights, anticancer activities, and comparative structure activity relationships of thiazolidin-4-one derivatives as EGFR inhibitors (2019-present)","volume":"128","author":"Elsisi","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib28","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118142_bib29","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1158\/1078-0432.CCR-06-0646","article-title":"Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs","volume":"12","author":"Ono","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib30","first-page":"S23","article-title":"EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients, Transl","volume":"8","author":"Karachaliou","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib31","first-page":"225","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2025.118142_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116106","article-title":"Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation","volume":"265","author":"Zuo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib33","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.2147\/OTT.S198945","article-title":"Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2025.118142_bib34","doi-asserted-by":"crossref","first-page":"9179","DOI":"10.1016\/j.arabjc.2020.10.041","article-title":"Novel benzimidazole derivatives as anti-cervical cancer agents of potential multi-targeting kinase inhibitory activity","volume":"13","author":"El-Meguid","year":"2020","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.6004\/jnccn.2013.0024","article-title":"Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers","volume":"11","author":"Yu","year":"2013","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ejmech.2025.118142_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118142_bib37","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1039\/D3RA02347H","article-title":"Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review","volume":"13","author":"Mansour","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118142_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jtho.2022.01.007","article-title":"The challenges of third-generation EGFR tyrosine kinase inhibitors in the therapy of advanced NSCLC","volume":"17","author":"Wang","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118142_bib39","first-page":"3929","article-title":"Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges, transl","volume":"13","author":"Su","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114900","article-title":"Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy","volume":"245","author":"Xu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib41","first-page":"1","article-title":"The advance of the third-generation EGFR-TKI in the treatment of non-small cell lung cancer","volume":"51","author":"Cheng","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2025.118142_bib42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.6026\/97320630019260","article-title":"Insights from the molecular docking analysis of EGFR antagonists","volume":"19","author":"Alam","year":"2023","journal-title":"Bioinformation"},{"key":"10.1016\/j.ejmech.2025.118142_bib43","first-page":"277","article-title":"Darbufelone, a novel anti-infammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo, cancer chemother","volume":"66","author":"Ye","year":"2010","journal-title":"Pharmacology (Basel)"},{"key":"10.1016\/j.ejmech.2025.118142_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106936","article-title":"Rational design and eco-friendly one-pot multicomponent synthesis of novel ethylidenehydrazineylthiazol-4(5H)-ones as potential apoptotic inducers targeting wild and mutant EGFR-TK in triple negative breast cancer","volume":"142","author":"Abbass","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib45","article-title":"New pyrazolyl-thiazolidinone\/thiazole derivatives as celecoxib\/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis, molecular modelling and ADME studies","volume":"38","author":"Fadaly","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib46","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.bmc.2016.05.063","article-title":"Toward discovery of mutant EGFR inhibitors; design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives","volume":"24","author":"Mowafy","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib47","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118142_bib48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/BJ20121513","article-title":"Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain","volume":"448","author":"Park","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2025.118142_bib49","first-page":"523","article-title":"Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of in-silico and in-vitro cytotoxicity methods","volume":"13","author":"Nasab","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.118142_bib50","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib51","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","article-title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","volume":"29","author":"Remon","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118142_bib52","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/0223-5234(96)88318-8","article-title":"New products neurotropic activity of aldehyde and ketone thiosemicarbazones with a heterocyclic component","author":"E Lukevics","year":"1995","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib53","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s00044-013-0708-z","article-title":"Design, synthesis and biological evaluation of some novel benzylidene-2-(4-phenylthiazol-2-yl) hydrazines as potential anti-inflammatory agents","volume":"23","author":"Bharti","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131902","article-title":"Sonochemical synthesis of the novel 1D zig-zag Hg(II)-Iodo bridged metal-organic coordination compounds with thiosemicarbazide derivative ligand","volume":"1250","author":"Hanifehpour","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118142_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.saa.2013.07.074","article-title":"Mn(II) and Cu(II) complexes of a bidentate Schiff's base ligand: spectral, thermal, molecular modelling and mycological studies","volume":"117","author":"Tyagi","year":"2014","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ejmech.2025.118142_bib56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/hc.2011.027","article-title":"Substituted 4-thiazolidinones under solvent free conditions","volume":"17","author":"Gautam","year":"2011","journal-title":"Heterocycl. Commun."},{"key":"10.1016\/j.ejmech.2025.118142_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/hc-2013-0197","article-title":"Synthesis and antimicrobial activity of some novel 2-thienyl substituted heterocycles","volume":"20","author":"Youssef","year":"2014","journal-title":"Heterocycl. Commun."},{"key":"10.1016\/j.ejmech.2025.118142_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.116534","article-title":"Inhibitive and adsorption behavior of new thiazoldinone derivative as a corrosion inhibitor at mild steel\/electrolyte interface: experimental and theoretical studies","volume":"338","author":"Masaret","year":"2021","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejmech.2025.118142_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103035","article-title":"Design, synthesis and anticervical cancer activity of new benzofuran\u2013pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents","volume":"89","author":"Abbas","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115674","article-title":"New series of isoxazole derivatives targeting EGFR-TK: synthesis, molecular modeling and antitumor evaluation","volume":"28","author":"Warda","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib61","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1007\/s00044-014-0926-z","article-title":"Synthesis and evaluation of anti-inflammatory and analgesic activity of some substituted thiazolyl and thaizolidinonyl tetrahydronapthalene derivatives","volume":"23","author":"Haiba","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib62","first-page":"1823","article-title":"Gefitinib suppresses cervical cancer progression by inhibiting cell cycle progression and epithelial-mesenchymal transition","author":"Zheng","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2025.118142_bib63","first-page":"3387","article-title":"Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity","volume":"26","author":"Suenaga","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-8-227","article-title":"Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines","volume":"8","author":"Solmi","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2025.118142_bib65","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1186\/s40169-019-0219-8","article-title":"EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non\u2010small cell lung cancer","volume":"8","author":"Phan","year":"2019","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118142_bib66","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models","volume":"75","author":"Eberlein","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib67","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118142_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216290","article-title":"Design, synthesis, and Antitumor activity evaluation of proteolysis-targeting chimeras as degraders of extracellular signal-regulated kinases 1\/2","volume":"24","author":"Pan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118142_bib69","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1039\/C8MD00197A","article-title":"Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant","volume":"9","author":"Zhang","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2025.118142_bib70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.lungcan.2014.05.008","article-title":"AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines","volume":"85","author":"Puglisi","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.118142_bib71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK pathway","volume":"1","author":"Molina","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118142_bib72","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bioorg.2018.10.044","article-title":"Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma","volume":"82","author":"Aly","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193344","article-title":"A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206","volume":"13","author":"Chorner","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118142_bib74","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib75","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014A visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib76","author":"Squire"},{"key":"10.1016\/j.ejmech.2025.118142_bib77","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/acs.jcim.8b00458","article-title":"Structural insights into characterizing binding sites in epidermal growth factor receptor kinase mutants","volume":"59","author":"Zhao","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118142_bib78","unstructured":"Molinspiration cheminformatics, (n.d.). https:\/\/www.molinspiration.com."},{"key":"10.1016\/j.ejmech.2025.118142_bib79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article: S0169-409X(96)00423-1","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2025.118142_bib80","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib81","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of drug absorption using multivariate statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib82","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"V Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2023.100422","article-title":"Pharmacokinetic analysis and structural optimization of inophyllamine-I to forecast as a possible drug candidate","volume":"3","author":"Kumar","year":"2023","journal-title":"Phytomed. Plus"},{"key":"10.1016\/j.ejmech.2025.118142_bib84","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118142_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24030416","article-title":"Design, synthesis, anticancer evaluation and molecular modeling of novel estrogen derivatives","volume":"24","author":"Amr","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118142_bib86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ab.2006.05.006","article-title":"Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery","volume":"356","author":"Jia","year":"2006","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2025.118142_bib87","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118142_bib88","series-title":"Anticancer Drug Dev. Guid. Preclin. Screening, Clin. Trials, Approv.","first-page":"41","article-title":"The NCI human tumor cell line (60-Cell) screen","author":"Boyd","year":"2004"},{"key":"10.1016\/j.ejmech.2025.118142_bib89","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","article-title":"Analysis of food and drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines","volume":"9","author":"Holbeck","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118142_bib90","article-title":"Effects of compound K, an enteric microbiome metabolite of ginseng, in the treatment of inflammation associated colon cancer","volume":"15","author":"Yao","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2025.118142_bib91","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canep.2009.06.003","article-title":"Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin","volume":"33","author":"Ho","year":"2009","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ejmech.2025.118142_bib92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13065-025-01402-8","article-title":"Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations","volume":"19","author":"Temirak","year":"2025","journal-title":"BMC Chem"},{"key":"10.1016\/j.ejmech.2025.118142_bib93","doi-asserted-by":"crossref","first-page":"38257","DOI":"10.1039\/C7RA03875E","article-title":"Underlying mechanism for the modulation of apoptosis induced by a new benzoindole derivative on HT-29 colon cancer cells","volume":"7","author":"Alipour","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118142_bib94","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejmech.2017.10.075","article-title":"Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7","volume":"143","author":"Abdelhaleem","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118292","article-title":"Design, synthesis, anticancer activity, and in silico computational studies of new imidazolone-based derivatives with potential multi-target kinase inhibitory activity","author":"Ahmed","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejmech.2025.118142_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137790","article-title":"Anticancer activity of new triazolopyrimidine linked coumarin and quinolone hybrids: synthesis, molecular modeling, TrkA, PI3K\/AKT and EGFR inhibition","volume":"1305","author":"Batran","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118142_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107058","article-title":"Design, synthesis, molecular docking and biological evaluation of 1,3,5-trisubstituted-1H-pyrazole derivatives as anticancer agents with cell cycle arrest, ERK and RIPK3- kinase activities","volume":"143","author":"Boshta","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118142_bib99","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1006\/jmbi.1996.0857","article-title":"PDB-based protein loop prediction: parameters for selection and methods for optimization11Edited","volume":"267","author":"van Vlijmen","year":"1997","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118142_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J. Cheminf."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:58:36Z","timestamp":1773122316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":100,"alternative-id":["S0223523425009079"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118142","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting EGFR with thiazolidin-4-ones: Structure-guided design, synthesis, and in silico profiling for anticancer drug discovery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118142"}}